Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

No correction vs. new formula for setting the anthropometric characteristics for Target Controlled Infusion (TCI) of remifentanil in obese patients. [Nessuna correzione vs nuova formula per l'mpostazione delle caratteristiche antropometriche per Target Controlled Infusion (TCI) di remifentanil in pazienti obesi.]

Trial Profile

No correction vs. new formula for setting the anthropometric characteristics for Target Controlled Infusion (TCI) of remifentanil in obese patients. [Nessuna correzione vs nuova formula per l'mpostazione delle caratteristiche antropometriche per Target Controlled Infusion (TCI) di remifentanil in pazienti obesi.]

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remifentanil (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 02 Apr 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top